Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
DUBLIN, April 20, 2018 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2018 on Tuesday, May 1, 2018. The Company has scheduled a conference call for that same day, Tuesday, May 1, 2018 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 |
| International: | 1-412-317-6581 |
| Conference ID #: | 10119605 |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/25538
A replay of the call can be accessed until May 8, 2018 by dialing:
| USA: | 1-877-344-7529 |
| International: | 1-412-317-0088 |
| Conference ID #: | 10119605 |
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/25538
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Contact
Kevin Tansley
Trinity Biotech plc
(353)-1-2769800
E-mail: [email protected]
Joe Diaz, Joe Dorame and Robert Blum
Lytham Partners, LLC
Investor Relations
602-889-9700
